| |  Online-Ressource |
|---|
| Verfasst von: | Eder, Matthias [VerfasserIn]  |
|---|
| | Kiß, Oliver [VerfasserIn] |
|---|
| | Müller, Miriam [VerfasserIn] |
|---|
| | Bauder-Wüst, Ulrike [VerfasserIn] |
|---|
| | Remde, Yvonne [VerfasserIn] |
|---|
| | Schäfer, Martin [VerfasserIn] |
|---|
| | Hennrich, Ute [VerfasserIn] |
|---|
| | Eisenhut, Michael [VerfasserIn] |
|---|
| | Afshar-Oromieh, Ali [VerfasserIn] |
|---|
| | Haberkorn, Uwe [VerfasserIn] |
|---|
| | Kopka, Klaus [VerfasserIn] |
|---|
| Titel: | Novel preclinical and radiopharmaceutical aspects of (68Ga)Ga-PSMA-HBED-CC |
|---|
| Titelzusatz: | a new PET tracer for imaging of prostate cancer |
|---|
| Verf.angabe: | Matthias Eder, Oliver Neels, Miriam Müller, Ulrike Bauder-Wüst, Yvonne Remde, Martin Schäfer, Ute Hennrich, Michael Eisenhut, Ali Afshar-Oromieh, Uwe Haberkorn and Klaus Kopka |
|---|
| E-Jahr: | 2014 |
|---|
| Jahr: | 30 June 2014 |
|---|
| Umfang: | 18 S. |
|---|
| Fussnoten: | Im Titel steht der Ausdruck (68Ga) in eckiger Klammer, die Zahl 68 ist dabei hochgestellt ; Gesehen am 17.02.2021 |
|---|
| Titel Quelle: | Enthalten in: Pharmaceuticals |
|---|
| Ort Quelle: | Basel : MDPI, 2004 |
|---|
| Jahr Quelle: | 2014 |
|---|
| Band/Heft Quelle: | 7(2014), 7, Seite 779-796 |
|---|
| ISSN Quelle: | 1424-8247 |
|---|
| Abstract: | The detection of prostate cancer lesions by PET imaging of the prostate-specific membrane antigen (PSMA) has gained highest clinical impact during the last years. 68Ga-labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-HBED-CC) represents a successful novel PSMA inhibitor radiotracer which has recently demonstrated its suitability in individual first-in-man studies. The radiometal chelator HBED-CC used in this molecule represents a rather rarely used acyclic complexing agent with chemical characteristics favourably influencing the biological functionality of the PSMA inhibitor. The simple replacement of HBED-CC by the prominent radiometal chelator DOTA was shown to dramatically reduce the in vivo imaging quality of the respective 68Ga-labelled PSMA-targeted tracer proving that HBED-CC contributes intrinsically to the PSMA binding of the Glu-urea-Lys(Ahx) pharmacophore. Owing to the obvious growing clinical impact, this work aims to reflect the properties of HBED-CC as acyclic radiometal chelator and presents novel preclinical data and relevant aspects of the radiopharmaceutical production process of [68Ga]Ga-PSMA-HBED-CC. |
|---|
| DOI: | doi:10.3390/ph7070779 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/ph7070779 |
|---|
| | Volltext: https://www.mdpi.com/1424-8247/7/7/779 |
|---|
| | DOI: https://doi.org/10.3390/ph7070779 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | <sup>68</sup>Ga-PET imaging |
|---|
| | GMP |
|---|
| | good manufacturing practice |
|---|
| | HBED-CC |
|---|
| | prostate cancer |
|---|
| | PSMA |
|---|
| | radiopharmaceutical production |
|---|
| K10plus-PPN: | 1748521888 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Novel preclinical and radiopharmaceutical aspects of (68Ga)Ga-PSMA-HBED-CC / Eder, Matthias [VerfasserIn]; 30 June 2014 (Online-Ressource)
